Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

150 µCiHMPL-523

Small molecule · developed by Hutchmed

Phase 1 Most advanced trial (none active)
HCM Developer
1 Registered trials

What is 150 µCiHMPL-523?

150 µCi HMPL-523 is a radiolabeled ([14C]) form of the small molecule HMPL-523, studied in a human mass balance trial in immune thrombocytopenia (ITP).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
150 µCi [14C]HMPL-523
Drug type
Small molecule
Therapy area
Hematology
Developer
Hutchmed (HCM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05781906 Phase 1 Imumune Thrombocytopenia(ITP) Human Mass Balance Completed HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Imumune Thrombocytopenia(ITP) Human Mass Balance

More from Hutchmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.

Follow HCM, the company behind 150 µCiHMPL-523

See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HCM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.